Linda Lebon

Linda Lebon has over 10 years of experience in regulatory affairs and strategy. Linda is currently working as the Chief Regulatory Officer at Apmonia Therapeutics, where they provide regulatory expertise and serves as a consultant. Prior to this, Linda worked as a regulatory strategic consultant at LRSS, where they supported the development and registration of biotech, biologic, and NCE products.

Linda has also held the position of Chief Regulatory Officer at Osivax, where they were responsible for regulatory activities. Linda has a strong background in regulatory strategy and project management, as demonstrated by their role as the Managing Director in Regulatory Strategy at Lebon Regulatory Science Strategy.

Linda has worked with numerous regulatory agencies, including the EMA, FDA, and PMDA, and has experience in various therapeutic areas. Linda has also served in interim roles, such as Head of Regulatory Affairs at OSE Immunotherapeutics.

In addition, Linda has held positions as a regulatory consultant at BONE THERAPEUTICS S.A., InhaTarget Therapeutics, and argenx. At argenx, they were the Vice President of Regulatory Affairs and led a team responsible for all regulatory needs within the biotech company.

Earlier in their career, Linda worked as a regulatory and drug development expert at Mithra and as the Director of Global Regulatory Science at Bristol-Myers Squibb. Overall, Linda Lebon's work experience showcases their expertise in regulatory affairs, strategic planning, and project management in the pharmaceutical industry.

Linda Lebon has a strong education background in the field of Molecular and Cellular Biology. From 1985 to 1994, they attended the University of Liège where they obtained a Master's degree in Molecular and Cellular Biology. Linda further pursued their education at the University of Liège from 1993 to 1994 and completed a program in Agregation en Sciences. In 1995-1996, Linda Lebon attended HEC Liège and earned a Certificat en gestion.